MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTX Stock Price Chart Interactive Chart >
MGTX Price/Volume Stats
|Current price||$13.59||52-week high||$18.45|
|Prev. close||$13.37||52-week low||$11.60|
|Day high||$13.81||Avg. volume||100,526|
|50-day MA||$13.40||Dividend yield||N/A|
|200-day MA||$14.60||Market Cap||602.24M|
MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio
MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.
Most Popular Stories View All
MGTX Latest News Stream
|Loading, please wait...|
MGTX Latest Social Stream
View Full MGTX Social Stream
Latest MGTX News From Around the Web
Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa
LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated in the Phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal function assessed 12 months following treatment with AAV5-RPGR
Shareholders in MeiraGTx Holdings plc ( NASDAQ:MGTX ) may be thrilled to learn that the analysts have just delivered a...
LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2021 and provided an update on recent progress.
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
MGTX Price Returns